TRT Side Effects: What Should You Actually Worry About?

Almost anyone who's ever typed 'TRT side effects' into a search engine has landed on the same mix: forum threads full of stories about heart attacks, cancer, and 'fertility destroyed forever,' interspersed with calm, technical descriptions lifted from package inserts. The problem is that these two sources rarely agree with each other, and it's hard for a layperson to judge which of the cited dangers are real and common, and which are isolated, sensationalized cases or myths already debunked decades ago. As a result, many men end up worrying about the wrong things — fearing a scenario that statistically almost never applies to them, while brushing off something far more likely, simply because it sounds less dramatic.

This article has a different purpose than our technical piece on monitoring therapy. Instead of listing every possible adverse effect in one flat paragraph, we've ranked them by how much they should actually weigh on your decision and your day-to-day life on TRT. We've split them into three tiers: common things that will affect almost everyone in some form, but are usually manageable; rarer but serious enough to deserve genuine vigilance and regular testing; and myths that scare the internet far more than today's evidence justifies.

Let's start with what's statistically most likely. These aren't dramatic complications out of sensational headlines — they're everyday, well-understood side effects that, in clinical practice, are the most common reason for follow-up visits and dose adjustments. None of them is inherently life-threatening, but each deserves your awareness before you see it on your own test result, or in your own mirror.

The most closely monitored and best-documented effect is erythrocytosis — an excessive rise in red blood cells and hematocrit. Testosterone stimulates erythropoietin production in the kidneys and improves iron utilization, so blood literally thickens. Depending on the delivery form and population studied, the frequency of elevated hematocrit (above 50%) ranges from a few percent to over 60% of patients — clearly more common with intramuscular injections, which produce larger hormone fluctuations than gels or patches. This isn't a rarity or an exception — it's the most common reason a doctor adjusts dose or injection frequency in the first year of therapy.

The second common effect is far less dangerous, but can be the most annoying day to day: oily skin and acne, especially on the back and chest. This results from androgens stimulating the sebaceous glands — a mechanism well known from puberty, just now triggered pharmacologically in an adult man. The third — mild fluid retention and slight swelling, especially noticeable at the start of therapy or after a dose increase, usually resolving on its own within a few weeks as the body adapts to the new, stable hormone level.

The fourth item in this tier concerns the testes and fertility — the only topic in this group that tends to be psychologically harder than medically dangerous. Testosterone given from outside suppresses LH and FSH secretion by the pituitary through negative feedback, which limits the testes' own hormone production and, in turn, sperm production, with a visible effect being noticeably reduced testicular volume. This happens to the vast majority of men on TRT without additional fertility-supporting treatment and is, in practice, the rule rather than the exception. The good news — why this ended up in the 'common but manageable' tier rather than on the list of serious threats — is explained in more detail in the myths section below, because this is one area where the internet tends to overreact in the opposite direction.

This tier covers risks that statistically affect a minority of patients, but which, unlike acne or swelling, have real, serious health consequences if they do occur. This is where most of the legitimately warranted concern about TRT safety lives — not in the prostate cancer myth.

For decades, the biggest question without a good answer was whether TRT increases the risk of heart attack, stroke, or cardiovascular death. In 2023, that question finally got a large, well-designed randomized trial — TRAVERSE, which enrolled over 5,200 men aged 45-80 with hypogonadism and existing or elevated cardiovascular risk. The result was reassuring: a composite endpoint of heart attack, stroke, and cardiovascular death occurred in 7% of participants on testosterone versus 7.3% on placebo — a difference that wasn't statistically significant. For the vast majority of men who qualify for therapy, this is one of the most reassuring pieces of news in the history of this topic.

The second real risk in this tier is less well known and easy to overlook: worsening of obstructive sleep apnea. Testosterone can affect upper airway muscle tone and alter breathing patterns during sleep, and in some men — especially those with already-diagnosed, untreated sleep apnea — therapy genuinely worsens sleep quality and safety, intensifying episodes of shallow or stopped breathing. That's why severe, untreated sleep apnea is treated as a contraindication to starting TRT until it's properly diagnosed and treated, for example with a CPAP machine.

And now the reason many readers opened this article in the first place — because these two topics are the ones that most often scare men away from even talking to a doctor about TRT, even though today's evidence calls for a significant revision.

This second myth is worth expanding on, because 'usually reversible' isn't the same as 'guaranteed and fast' — and honesty requires both caveats at once. A pooled analysis of data from hormonal male contraception research (the spermatogenesis suppression mechanism there is practically identical to TRT) found that in most men sperm count returns to values above 20 million per milliliter within 6 months of stopping testosterone, in another portion it takes 12-24 months, and in a small percentage recovery is incomplete or very slow — especially in older men and those who used therapy the longest.

The practical takeaway is therefore more measured than either extreme circulating online: 'TRT definitely won't affect fertility' is false, but so is 'TRT destroys fertility forever.' If you're planning fatherhood in the coming years, that's not a reason to rule out therapy outright, but it's absolutely enough reason to discuss fertility-protection strategies with your doctor (e.g. hCG during therapy) or consider banking sperm before starting — rather than finding out about this problem after the fact.

The table below collects the effects described above in one place, so you can easily return to it later without scrolling back through the whole article.

If you take one thing away from this article, let it be a sense of priorities rather than a list of fears. Erythrocytosis, acne, fluid retention, and the effect on fertility are things that, in some form, will affect most TRT patients — and it's these, not heart attacks or prostate cancer, that should be the first topic of conversation with your doctor about what to expect and how to monitor it day to day. Atrial fibrillation and worsening sleep apnea are rarer, but serious enough to deserve a separate, explicit question during qualification for therapy, especially if you have a history of either. And the classic fear of prostate cancer and 'permanent infertility' — while understandable, having been repeated as a certainty for decades — deserves a clear easing today in light of the evidence, without dismissing the need for monitoring itself.